var data={"title":"Valacyclovir: An overview","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Valacyclovir: An overview</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/valacyclovir-an-overview/contributors\" class=\"contributor contributor_credentials\">Kimon C Zachary, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/valacyclovir-an-overview/contributors\" class=\"contributor contributor_credentials\">Martin S Hirsch, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/valacyclovir-an-overview/contributors\" class=\"contributor contributor_credentials\">Jennifer Mitty, MD, MPH</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/valacyclovir-an-overview/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Nov 08, 2016.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=valacyclovir-drug-information\" class=\"drug drug_general\">Valacyclovir</a> is the valyl ester of the antiviral drug <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a>&nbsp;[<a href=\"https://www.uptodate.com/contents/valacyclovir-an-overview/abstract/1\" class=\"abstract_t\">1</a>]. Acting as an oral prodrug, valacyclovir is converted in vivo to acyclovir. Acyclovir, a nucleoside analog, is phosphorylated by virally-encoded thymidine kinase and subsequently by cellular enzymes, yielding acyclovir triphosphate, which competitively inhibits viral DNA polymerase. (See <a href=\"topic.htm?path=acyclovir-an-overview\" class=\"medical medical_review\">&quot;Acyclovir: An overview&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">BASIC PHARMACOKINETICS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The antiviral activity of <a href=\"topic.htm?path=valacyclovir-drug-information\" class=\"drug drug_general\">valacyclovir</a> reflects its in vivo conversion to <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a>, which is active against herpes simplex viruses types 1 and 2, varicella-zoster virus, and Epstein-Barr virus. Cytomegalovirus (CMV), which does not encode thymidine kinase, is resistant at the oral doses approved by the US Food and Drug Administration [<a href=\"https://www.uptodate.com/contents/valacyclovir-an-overview/abstract/2,3\" class=\"abstract_t\">2,3</a>]. </p><p><a href=\"topic.htm?path=valacyclovir-drug-information\" class=\"drug drug_general\">Valacyclovir</a> has three to fivefold greater oral bioavailability (about 55 percent) than <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a>; it then undergoes rapid and extensive first-pass intestinal <span class=\"nowrap\">and/or</span> hepatic hydrolysis to yield acyclovir and L-valine [<a href=\"https://www.uptodate.com/contents/valacyclovir-an-overview/abstract/2,3\" class=\"abstract_t\">2,3</a>]. Food does not affect absorption.</p><p><a href=\"topic.htm?path=valacyclovir-drug-information\" class=\"drug drug_general\">Valacyclovir</a>, at a dose of 250 mg four times daily, generates essentially the same <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a> AUC (area under the curve, or exposure over 24 hours) as oral acyclovir at a dose 800 mg five times daily [<a href=\"https://www.uptodate.com/contents/valacyclovir-an-overview/abstract/3\" class=\"abstract_t\">3</a>]. Valacyclovir, at a dose of 1000 mg three times daily, produces a similar acyclovir AUC as intravenous acyclovir at a dose of 5 <span class=\"nowrap\">mg/kg</span> every eight hours [<a href=\"https://www.uptodate.com/contents/valacyclovir-an-overview/abstract/4\" class=\"abstract_t\">4</a>].</p><p>Intravenous <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a> generates higher peak levels than oral <a href=\"topic.htm?path=valacyclovir-drug-information\" class=\"drug drug_general\">valacyclovir</a>. Although this feature may confer more potent activity, it may also increase the risk of renal toxicity due to precipitation of acyclovir crystals in the renal tubules [<a href=\"https://www.uptodate.com/contents/valacyclovir-an-overview/abstract/3\" class=\"abstract_t\">3</a>] (see <a href=\"topic.htm?path=crystal-induced-acute-kidney-injury-acute-renal-failure\" class=\"medical medical_review\">&quot;Crystal-induced acute kidney injury (acute renal failure)&quot;</a>). On the other hand, the safety of high-dose oral valacyclovir, especially in immunocompromised persons, remains controversial.</p><p>The main route of <a href=\"topic.htm?path=valacyclovir-drug-information\" class=\"drug drug_general\">valacyclovir</a> elimination is renal, and dose modification is recommended for patients with a creatinine clearance below 30 <span class=\"nowrap\">mL/min/1</span>.73 m2. Dose adjustment is not required in patients with hepatic impairment [<a href=\"https://www.uptodate.com/contents/valacyclovir-an-overview/abstract/3\" class=\"abstract_t\">3</a>].</p><p class=\"headingAnchor\" id=\"H499155513\"><span class=\"h1\">MECHANISM OF RESISTANCE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The mechanisms of resistance to <a href=\"topic.htm?path=valacyclovir-drug-information\" class=\"drug drug_general\">valacyclovir</a> are identical to those described for <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a>. Three mechanisms have been shown to endow herpes simplex viruses with resistance to acyclovir, a phenomenon rare in the immunocompetent host [<a href=\"https://www.uptodate.com/contents/valacyclovir-an-overview/abstract/5\" class=\"abstract_t\">5</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Reduced or absent thymidine kinase</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Altered thymidine kinase activity resulting in decreased <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a> phosphorylation</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Altered viral DNA polymerase with decreased affinity for <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a> triphosphate</p><p/><p>(See <a href=\"topic.htm?path=acyclovir-an-overview#H4\" class=\"medical medical_review\">&quot;Acyclovir: An overview&quot;, section on 'Mechanism of resistance'</a>.)</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h1\">TOXICITY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>When administered at approved doses (up to 1000 mg three times daily), <a href=\"topic.htm?path=valacyclovir-drug-information\" class=\"drug drug_general\">valacyclovir</a> has been remarkably well tolerated, similar to the experience with <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a>&nbsp;[<a href=\"https://www.uptodate.com/contents/valacyclovir-an-overview/abstract/1,3\" class=\"abstract_t\">1,3</a>]. </p><p>However, a trial examining the effectiveness of high-dose <a href=\"topic.htm?path=valacyclovir-drug-information\" class=\"drug drug_general\">valacyclovir</a> (2000 mg four times daily) in preventing cytomegalovirus (CMV) disease was halted when interim analysis revealed significantly shorter survival in patients receiving this regimen [<a href=\"https://www.uptodate.com/contents/valacyclovir-an-overview/abstract/6\" class=\"abstract_t\">6</a>]. This complication has also been observed at this high dose in recipients of allogeneic bone marrow or kidney transplants [<a href=\"https://www.uptodate.com/contents/valacyclovir-an-overview/abstract/1\" class=\"abstract_t\">1</a>].</p><p>Much of this phenomenon was attributed to the development of a thrombotic microangiopathy associated with <a href=\"topic.htm?path=valacyclovir-drug-information\" class=\"drug drug_general\">valacyclovir</a>; however, causality has not been established conclusively, since several other medications (<a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a>, <a href=\"topic.htm?path=ethambutol-drug-information\" class=\"drug drug_general\">ethambutol</a>, <a href=\"topic.htm?path=clofazimine-united-states-available-via-national-hansens-disease-program-and-fda-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">clofazimine</a>, <a href=\"topic.htm?path=trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information\" class=\"drug drug_general\">trimethoprim-sulfamethoxazole</a>) were also significantly associated with this complication [<a href=\"https://www.uptodate.com/contents/valacyclovir-an-overview/abstract/7\" class=\"abstract_t\">7</a>]. (See <a href=\"topic.htm?path=drug-induced-thrombotic-microangiopathy\" class=\"medical medical_review\">&quot;Drug-induced thrombotic microangiopathy&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h1\">USE IN PREGNANCY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=valacyclovir-drug-information\" class=\"drug drug_general\">Valacyclovir</a> has been assigned to Pregnancy Category B, which denotes no clear evidence of risk in humans despite the lack of controlled studies documenting safety. Thus, for pregnant women, the potential benefits may outweigh the potential risks to the fetus. In addition, prospective epidemiologic registries found that the rate of birth defects among 749 women exposed to systemic <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a> during the first trimester was not significantly different from that of the general population [<a href=\"https://www.uptodate.com/contents/valacyclovir-an-overview/abstract/1\" class=\"abstract_t\">1</a>]. However, the relatively small size of the registry yielded insufficient power to draw reliable or definitive conclusions regarding the safety of acyclovir in pregnancy. </p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h1\">CLINICAL USE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=valacyclovir-drug-information\" class=\"drug drug_general\">Valacyclovir</a> can generally be regarded as an acceptable alternative to oral <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a> when this drug is indicated and features a more convenient dosing schedule. The use of valacyclovir in such conditions is discussed elsewhere. (See <a href=\"topic.htm?path=b-virus-infection\" class=\"medical medical_review\">&quot;B virus infection&quot;</a> and <a href=\"topic.htm?path=treatment-of-herpes-zoster-in-the-immunocompetent-host\" class=\"medical medical_review\">&quot;Treatment of herpes zoster in the immunocompetent host&quot;</a> and <a href=\"topic.htm?path=treatment-of-genital-herpes-simplex-virus-infection\" class=\"medical medical_review\">&quot;Treatment of genital herpes simplex virus infection&quot;</a> and <a href=\"topic.htm?path=treatment-of-herpes-simplex-virus-type-1-infection-in-immunocompetent-patients\" class=\"medical medical_review\">&quot;Treatment of herpes simplex virus type 1 infection in immunocompetent patients&quot;</a>.) </p><p class=\"headingAnchor\" id=\"H1564280\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=valacyclovir-drug-information\" class=\"drug drug_general\">Valacyclovir</a> is converted in vivo to <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a>, a nucleoside analog that competitively inhibits viral DNA polymerase. (See <a href=\"#H1\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=valacyclovir-drug-information\" class=\"drug drug_general\">Valacyclovir</a> is active in vitro against herpes simplex viruses types 1 and 2, varicella-zoster virus, and Epstein-Barr virus (EBV), but is not usually used clinically for EBV infections. Valacyclovir has three to fivefold greater oral bioavailability (about 55 percent) than <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a>. (See <a href=\"#H2\" class=\"local\">'Basic pharmacokinetics'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The mechanism of resistance to <a href=\"topic.htm?path=valacyclovir-drug-information\" class=\"drug drug_general\">valacyclovir</a> is identical to that described for <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a>. Three mechanisms have been shown to endow herpes simplex viruses with resistance to acyclovir, a phenomenon rare in the immunocompetent host: reduced or absent thymidine kinase, altered thymidine kinase activity, and altered viral DNA polymerase with decreased affinity for acyclovir triphosphate. (See <a href=\"#H499155513\" class=\"local\">'Mechanism of resistance'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>When administered at approved doses (up to 1000 mg three times daily), <a href=\"topic.htm?path=valacyclovir-drug-information\" class=\"drug drug_general\">valacyclovir</a> is well tolerated. (See <a href=\"#H3\" class=\"local\">'Toxicity'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=valacyclovir-drug-information\" class=\"drug drug_general\">Valacyclovir</a> has been assigned to Pregnancy Category B, which denotes no clear evidence of risk in humans despite the lack of controlled studies documenting safety. (See <a href=\"#H4\" class=\"local\">'Use in pregnancy'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=valacyclovir-drug-information\" class=\"drug drug_general\">Valacyclovir</a> can generally be regarded as an acceptable alternative to oral <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a> when this drug is indicated and offers a more convenient dosing schedule. (See <a href=\"#H5\" class=\"local\">'Clinical use'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li class=\"breakAll\">Valtrex (valacyclovir hydrochloride) prescribing information, Glaxo Wellcome Inc, 2013. https://www.gsksource.com/gskprm/htdocs/documents/VALTREX-PI-PIL.PDF.</li><li><a href=\"https://www.uptodate.com/contents/valacyclovir-an-overview/abstract/2\" class=\"nounderline abstract_t\">Alrabiah FA, Sacks SL. New antiherpesvirus agents. Their targets and therapeutic potential. Drugs 1996; 52:17.</a></li><li><a href=\"https://www.uptodate.com/contents/valacyclovir-an-overview/abstract/3\" class=\"nounderline abstract_t\">Perry CM, Faulds D. Valaciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections. Drugs 1996; 52:754.</a></li><li><a href=\"https://www.uptodate.com/contents/valacyclovir-an-overview/abstract/4\" class=\"nounderline abstract_t\">H&ouml;glund M, Ljungman P, Weller S. Comparable aciclovir exposures produced by oral valaciclovir and intravenous aciclovir in immunocompromised cancer patients. J Antimicrob Chemother 2001; 47:855.</a></li><li><a href=\"https://www.uptodate.com/contents/valacyclovir-an-overview/abstract/5\" class=\"nounderline abstract_t\">Chatis PA, Crumpacker CS. Resistance of herpesviruses to antiviral drugs. Antimicrob Agents Chemother 1992; 36:1589.</a></li><li><a href=\"https://www.uptodate.com/contents/valacyclovir-an-overview/abstract/6\" class=\"nounderline abstract_t\">Feinberg JE, Hurwitz S, Cooper D, et al. A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group. J Infect Dis 1998; 177:48.</a></li><li><a href=\"https://www.uptodate.com/contents/valacyclovir-an-overview/abstract/7\" class=\"nounderline abstract_t\">Bell WR, Chulay JD, Feinberg JE. Manifestations resembling thrombotic microangiopathy in patients with advanced human immunodeficiency virus (HIV) disease in a cytomegalovirus prophylaxis trial (ACTG 204). Medicine (Baltimore) 1997; 76:369.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 8337 Version 9.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H1564280\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">BASIC PHARMACOKINETICS</a></li><li><a href=\"#H499155513\" id=\"outline-link-H499155513\">MECHANISM OF RESISTANCE</a></li><li><a href=\"#H3\" id=\"outline-link-H3\">TOXICITY</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">USE IN PREGNANCY</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">CLINICAL USE</a></li><li><a href=\"#H1564280\" id=\"outline-link-H1564280\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=acyclovir-an-overview\" class=\"medical medical_review\">Acyclovir: An overview</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=b-virus-infection\" class=\"medical medical_review\">B virus infection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=crystal-induced-acute-kidney-injury-acute-renal-failure\" class=\"medical medical_review\">Crystal-induced acute kidney injury (acute renal failure)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=drug-induced-thrombotic-microangiopathy\" class=\"medical medical_review\">Drug-induced thrombotic microangiopathy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-genital-herpes-simplex-virus-infection\" class=\"medical medical_review\">Treatment of genital herpes simplex virus infection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-herpes-simplex-virus-type-1-infection-in-immunocompetent-patients\" class=\"medical medical_review\">Treatment of herpes simplex virus type 1 infection in immunocompetent patients</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-herpes-zoster-in-the-immunocompetent-host\" class=\"medical medical_review\">Treatment of herpes zoster in the immunocompetent host</a></li></ul></div></div>","javascript":null}